Evotec SE

Evotec-partner Jingxin receives approval for EVT201 in China

Evotec presents precision medicine platforms for accelerated pipeline building at Capital Markets Day

Evotec SE reports results for the first nine months 2023 and provides corporate update

Evotec and Dewpoint Therapeutics enter strategic partnership in oncology

Evotec SE to announce results for the first nine months 2023 on 08 November 2023

Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch ’65LAB’

Evotec SE: Launch of partnering agreement to strengthen biotech innovators in shared R&D economy

Evotec and Novo Nordisk launch LAB eN² to accelerate translation in cardiometabolic diseases

Evotec SE reports results for the first half-year 2023 and provides corporate updates

Evotec SE reports first half-year 2023 results on 29 August 2023

Evotec provides update on financial impact of cyber-attack

Evotec provides update on financial impact of cyber-attack

Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership

Just – Evotec Biologics awarded second contract from U.S. Department of Defense under accelerated antibodies program

Evotec receives milestone payment for first patient dosed in Phase I study of Bayer kidney disease programme

Evotec SE Annual General Meeting 2023 approves all proposed agenda items

Evotec presents sustainability strategy

Evotec receives grant from Open Philanthropy for discovery of RNA-targeting Henipavirus therapeutics

Evotec SE: Bekanntmachung der Einberufung zur Hauptversammlung am 20.06.2023 in Hamburg mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023

Just – Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing

Just – Evotec Biologics enters strategic biosimilars partnership with Sandoz